FatiAbGen Inc.
Best in class multi-modality antibodies for difficult targets in high unmet need diseases in oncology and immunology
9 employees · est. 2020 · Korea South
Memo Therapeutics AG is the older company (2020 vs 2012); Memo Therapeutics AG is the larger of the two.
2 signals in the last 90 days
Side-by-Side Comparison
| Metric | FatiAbGen Inc. | Memo Therapeutics AG |
|---|---|---|
| Founded | ||
| Founded | 2020 | 2012 older |
| Headquarters | ||
| Headquarters | Korea South | Schlieren, Switzerland |
| Employees | ||
| Employees | 9 | 32 larger |
| Industry | ||
| Industry | Biopharma, Biotechnology, Pharmaceutical | Biotechnology |
| Funding Stage | ||
| Funding Stage | Seed | Series C |
| Total Funding | ||
| Total Funding | $3.00M | $99.80M |
| Funding Rounds | ||
| Funding Rounds | 2 | 7 |
| Services | ||
| Services | Antibody Drug Development, Research in Oncology and Immunology, Joint R&D Collaborations | Development of therapeutic antibodies, Antibody isolation and identification, Clinical trials for BKPyV treatment, Antibody repertoire mining, Collaboration for oncology and virology medicines |
| Target Customers | ||
| Target Customers | Healthcare Providers, Biotech Firms, Pharmaceutical Companies, Academic and Research Institutions | Kidney transplant recipients, Patients with viral infections, Cancer patients, Healthcare providers, Research institutions |
| Taxonomy | ||
| Taxonomy | Multi-modality Antibodies, Oncology Therapeutics, Immunology Therapeutics, Antibody Engineering, Biotech Collaboration, Shonan IPark, JLABS Member, Pre-clinical Pipeline, Antibody-drug Conjugates, Bi-specific Antibodies, CAR-T Technology, Mesothelin Targeting, Solid Tumor Treatment, MSLN ADC, IgE Therapies | Antibody Discovery, Immune Repertoire Analysis, Innovator, Therapeutic Antibodies, Microfluidic Screening, High Throughput Analysis, Recombinant Technology, Antibody Libraries, CAR-T Screening, TCR-T Screening, Bi-specific Antibodies, Immunology, Pharmaceuticals, Immunotherapy |
| Website | ||
| Website | fatiabgen.com | memo-therapeutics.com |
About FatiAbGen Inc.
FatiAbGen Inc., founded in 2020, is an innovative player in the Biopharma, Biotechnology, and Pharmaceutical industries. The company's slogan, "Best in class multi-modality antibodies for difficult targets in high unmet need diseases in oncology and immunology," highlights its commitment to developi...
About Memo Therapeutics AG
Memo Therapeutics AG (MTx), founded in 2012, is a promising late-stage biotech company situated in Switzerland. The company is dedicated to turning unique human immune responses into superior medicines. With a strong focus on biotechnology, MTx specializes in the development of best-in-class antibod...
We will tell you when either one moves
BounceWatch watches FatiAbGen Inc. and Memo Therapeutics AG for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at FatiAbGen Inc. and Memo Therapeutics AG — by email.
Frequently Asked Questions
Compare FatiAbGen Inc. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at FatiAbGen Inc. on 12 Mar 2026, and Memo Therapeutics AG on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
